Evaluating Rivaroxaban for Thromboprophylaxis in Cancer Patients with Long-Term Venous Access Devices: A Retrospective Cohort Study.

Vasc Health Risk Manag · 2025 · PMC12596838 · PMID 41215801

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While PORT patients did not reach statistical significance overall, exclusion of low-risk individuals revealed a protective effect, suggesting that selection criteria strongly influence outcomes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.